CD8A and neoplasm: Tumor immunotherapies employing immune checkpoint blockade (ICB) or adoptive cell transfer have shown significant clinical success across various malignancies, yet low response rates persist.[1] It is well‐established that tumor immunotherapy aims to generate long‐term, potent CD8+ cytotoxic T lymphocytes (CTLs) closely linked to clinical tumor response.[2]